| Literature DB >> 27270433 |
L A Selth1,2,3, R Das1,2,3, S L Townley1,2,3, I Coutinho1,2,3, A R Hanson1,2,3, M M Centenera2,3,4, N Stylianou5, K Sweeney5, C Soekmadji5, L Jovanovic5, C C Nelson5, A Zoubeidi6, L M Butler2,3,4, G J Goodall3,7,8, B G Hollier5, P A Gregory3,7, W D Tilley1,2,3.
Abstract
MicroRNA-375 (miR-375) is frequently elevated in prostate tumors and cell-free fractions of patient blood, but its role in genesis and progression of prostate cancer is poorly understood. In this study, we demonstrated that miR-375 is inversely correlated with epithelial-mesenchymal transition signatures (EMT) in clinical samples and can drive mesenchymal-epithelial transition (MET) in model systems. Indeed, miR-375 potently inhibited invasion and migration of multiple prostate cancer lines. The transcription factor YAP1 was found to be a direct target of miR-375 in prostate cancer. Knockdown of YAP1 phenocopied miR-375 overexpression, and overexpression of YAP1 rescued anti-invasive effects mediated by miR-375. Furthermore, transcription of the miR-375 gene was shown to be directly repressed by the EMT transcription factor, ZEB1. Analysis of multiple patient cohorts provided evidence for this ZEB1-miR-375-YAP1 regulatory circuit in clinical samples. Despite its anti-invasive and anti-EMT capacities, plasma miR-375 was found to be correlated with circulating tumor cells in men with metastatic disease. Collectively, this study provides new insight into the function of miR-375 in prostate cancer, and more broadly identifies a novel pathway controlling epithelial plasticity and tumor cell invasion in this disease.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27270433 DOI: 10.1038/onc.2016.185
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867